Health Minister Patty Hajdu (Thunder Bay-Superior North, Ont.) tabled the 2019 Annual Report of the Patented Medicine Prices Review Board with the Clerks of the House of Commons and the Senate. The 2019 Annual Report outlines the continuing rise in the sales of high-cost drugs in Canada. Sales of patented drugs grew to over $17 billion … Read more
The latest edition of the Patented Medicine Prices Review Board Meds Entry Watch reports that 40 new-to-Canada medicines were approved for market in 2018, of which 22 had reported sales by the end of 2019. This is in line with the annual rate of approximately nine new approvals per quarter since 2015, a trend that continued … Read more
The latest edition of the Patented Medicine Prices Review Board, Meds Pipeline Monitor, reports that oncology continued to dominate the therapeutic mix of the drug pipeline in 2020, with cancer treatments representing one third (35 per cent) of medicines in all phases of clinical trials. Treatments for infectious diseases held the second largest share of the pipeline, … Read more
The Patented Medicine Prices Review Board invites stakeholders to comment on two proposed consequential amendments to the new PMPRB Guidelines resulting from the decision to delay the coming-into-force date of the Regulations Amending the Patented Medicines Regulations a further six months, from January 1, 2021 to July 1, 2021. The PMPRB proposes to change the … Read more
The latest edition of the Patented Medicine Prices Review Board’s CompassRx report reveals that prescription drug expenditures for the National Prescription Drug Utilization Information System (NPDUIS) public drug plans increased by 5.6 per cent in 2018/19 to reach $12.1 billion, driven primarily by a considerable rise in the use of higher-cost drugs coupled with greater … Read more
The PMPRB, under the National Prescription Drug Utilization Information System initiative, released a chartbook on the market for oncology medicines in Canada. The Oncology Medicines in Canada chartbook examines Canadian and international trends in the sales, pricing, market distribution, and treatment costs of oncology medicines from 2010 to 2019, highlighting the rapid growth in this increasingly … Read more
The Patented Medicine Prices Review Board released the final version of the PMPRB Guidelines. The release of the Guidelines is the culmination of a five-year process to strengthen and modernize the pricing framework for patented drugs in Canada, and follows on the heels of Health Canada’s August 2019 amendment to the Patented Medicines Regulations. The new Guidelines … Read more
The Patented Medicine Prices Review Board launched a 30-day public consultation on its updated draft pricing guidelines, which have been significantly changed in response to stakeholder feedback on an earlier draft that was released in November 2019 for an 85-day consultation period. The guidelines explain the steps taken by staff at the PMPRB in assessing … Read more
The latest edition of the Patented Medicine Prices Review Board (PMPRB) Meds Pipeline Monitor reports that oncology treatments made up over a third of the more than 5,500 new drugs in all phases of clinical trials in 2019. Meds Pipeline Monitor 2019 reviewed the 697 new medicines in late stages of clinical evaluation to highlight drugs … Read more
Findings from the latest edition of the PMPRB’s Meds Entry Watch report show a continued rise in the number of new specialized treatments entering international markets. Coupled with high treatment costs, specialty orphan and cancer medicines now account for a sizable share of the new drug landscape. From 2009 to 2017, slightly less than half of all new … Read more
